Company profile
FENNEC PHARMACEUTICALS INC.
NASDAQ:FENCBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PEDMARK | approved | $15.1MQ1 2026 | 0 | — |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (0)
No records yet.
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 212937 | 2022-09-20 | NDA | FENNEC PHARMACEUTICALS INC | |||||
Loading… | ||||||||